申请人:Warner-Lambert Company
公开号:US05432181A1
公开(公告)日:1995-07-11
The present invention is novel compounds which are 4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidine substituted 1,2,4- and 1,3,4-thiadiazoles and oxadiazoles, and 1,2,4-triazoles, and pharmaceutically acceptable additions and base salts thereof, pharmaceutical compositions and methods of use therefor. The invention compounds are now found to have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase providing treatment of conditions advantageously affected by such inhibition including inflammation, arthritis, pain, fever, and particularly rheumatoid arthritis, osteoarthritis, other inflammatory conditions, psoriasis, allergic diseases, asthma, inflammatory bowel disease, GI ulcers, cardiovascular conditions, including ischemic heart disease and atherosclerosis, and ischemia-induced cell damage, particularly brain damage caused by stroke. They can also be used topically for treating acne, sunburn, psoriasis, and eczema. Also included are leukotriene mediated pulmonary, gastrointestinal, inflammatory, dermatological, and cardiovascular conditions. The disclosed compounds also have potential utility as antioxidants. The preferred use is in treating inflammatory conditions.
本发明涉及新型化合物,其为4,6-二叔丁基-5-羟基-1,3-嘧啶取代的1,2,4-和1,3,4-噻二唑、噁二唑和1,2,4-三唑化合物,以及其药学上可接受的补充物和盐基,药物组合物和使用方法。发明化合物现已发现具有5-脂氧合酶和/或环氧化酶抑制剂的活性,可用于治疗受到这种抑制优势影响的疾病,包括炎症、关节炎、疼痛、发热,特别是类风湿性关节炎、骨关节炎、其他炎症性疾病、牛皮癣、过敏性疾病、哮喘、炎症性肠病、胃肠溃疡、心血管疾病,包括缺血性心脏病和动脉粥样硬化,以及缺血引起的细胞损伤,尤其是中风引起的脑损伤。它们也可以用于局部治疗痤疮、晒伤、牛皮癣和湿疹。还包括白三烯介导的肺部、胃肠道、炎症、皮肤和心血管疾病。所披露的化合物也具有作为抗氧化剂的潜在用途。首选用途是治疗炎症性疾病。